ClinicalTrials.gg
Active, not recruitingNCT05198557Updated Dec 8, 2025

A Study of MT-0551 in Patients With Systemic Sclerosis

A Phase 3 interventional study of Inebilizumab and Placebo in Systemic Sclerosis, sponsored by Tanabe Pharma Corporation. Active, not recruiting at 4 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Scleroderma, Systemic with a site in Japan — 4 open to participants now, 6 under way, 6 of them phase 3. Scleroderma, Systemic · Japan.

Planned enrollment
12th of 18
80 · median 111
Started
2022
with 3 others
Phase 3
9 of 18
3 open now
Registered
10th of 18
by date

Among the 18 studies in Scleroderma, Systemic with a site in Japan, this one is the 12th largest by planned enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 10th registered.

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

4 of the 18 studies in Scleroderma, Systemic with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 145 Scleroderma, Systemic studies recruiting now, 83 (57%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Scleroderma, Systemic with a site in Japan, or all of them as a file.
02

Study summary

The study will verify the superiority of MT-0551 to placebo at 26 weeks after treatment initiation in systemic sclerosis (SSc) patients using the modified Rodnan Total Skin thickness Score (mRTSS) as a measure of skin thickening. The safety and pharmacokinetics will also be investigated.

03

Conditions studied

  • Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Additional screening criteria check may apply for qualification:

  1. ACR/European League Against Rheumatism (EULAR) criteria (2013) systemic sclerosis (SSc) diagnostic criteria satisfied.
  2. Skin thickening score based on the mRTSS between 10 and 22 inclusive.

Exclusion criteria

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

  1. Pulmonary hypertension associated with SSc.
  2. Presence of a serious, SSc-related concurrent illness other than interstitial pneumonia.
  3. Finding of inadequate respiratory reserve capacity.
  4. Past history of rituximab, blinatumomab, obinutuzumab, or ofatumumab.
  5. Presence of a active infection requiring antimicrobial therapy.
  6. A past history of cancer.
  7. Past history of a recurrent, clinically significant infection.
  8. Past history of severe allergy or anaphylactic reaction to a biologic drug product.
  9. Treatment with within a certain period (inactivated vaccine is acceptable).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    MT-0551 group

    Participants will receive intravenous (IV) inebilizumab on Day 1 and Day 15 of randomized controlled period (RCP). The participants who entered open label period (OLP) will receive IV inebilizumab on Day 1 and IV placebo on Day 15 of OLP and will be followed by IV inebilizumab every 26 weeks.

    Drug: Inebilizumab · Drug: Placebo

  • Placebo comparator
    Placebo group

    Participants will receive IV placebo on Day 1 and Day 15 of the RCP. The participants who entered OLP will receive IV inebilizumab on both Day 1 and Day 15 in OLP and will be followed by IV inebilizumab every 26 weeks.

    Drug: Inebilizumab · Drug: Placebo

Interventions

  • Participants will receive IV inebilizumab.

    Also known as: MT-0551

  • DrugPlacebo

    Participants will receive IV placebo matched to inebilizumab.

06

What researchers measure

Primary outcomes

  1. Change from baseline in the mRTSS up to the end of the long-term extension period

    Time frame: baseline, RCP 4, 12, 26, OLP 4,12, 26, the long-term extension period 26, 52, 78, 104 weeks

Secondary outcomes

  1. Pulmonary function tests: Change from baseline in the percent predicted forced vital capacity (%FVC) and percent predicted diffusing capacity of the lung carbon monoxide (%DLco)

    Time frame: Baseline to at least 52 weeks or early termination

  2. Pulmonary function tests: Percentage change from baseline in the %FVC and %DLco

    Time frame: Baseline to at least 52 weeks or early termination

  3. Change from baseline in the mRTSS

    Time frame: Baseline to at least 52 weeks or early termination

  4. Composite response index in diffuse cutaneous systemic sclerosis

    Time frame: Week 26 to at least 52 weeks or early termination

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2025, 36 months.

Of 17 phase 3 interventional studies under Scleroderma, Systemic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 54. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2022
First posted
Jan 20, 2022
StartActual
Jul 20, 2022
Primary completionActual
Jul 31, 2025
CompletionEst.
Aug 2026
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05198557
Responsible party
Sponsor
First posted
Jan 20, 2022
Start date
Jul 20, 2022
Primary completion
Jul 31, 2025
Completion
Aug 2026 (estimated)
Last update
Dec 8, 2025

Study contacts

General Manager
study director · Tanabe Pharma Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion